Repotrectinib TRIDENT-1



Repotrectinib TRIDENT-1 PRELIMINARY SCORE CURATIVE CURATIVE Overall Survival / Disease-Free Survival / Pathological Complete Response NON-CURATIVE NON-CURATIVE Overall Survival Overall Survival Progression-Free Survival Progression-Free Survival Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate Overall Survival Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate Overall Survival / Disease-Free Survival / Pathological Complete Response Overall Survival / Disease-Free Survival / Pathological Complete Response Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate Overall Survival / Disease-Free Survival / Pathological Complete Response Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate		
CURATIVE Overall Survival / Disease-Free Survival / Pathological Complete Response NON-CURATIVE NON-CURATIVE Overall Survival Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate Overall Survival / Disease-Free Survival Overall Survival / Disease-Free Survival / Pathological Complete Response Overall Survival / Disease-Free Survival Overall Survival / Disease-Free Survival / Pathological Complete Response Overall Survival / Disease-Free Survival / Pathological Complete Response	Repotrectinib TRIDENT-1	Repotrectinib TRIDENT-1
NON-CURATIVE ADJUSTMENTS Quality of life Progression-Free Survival / Disease-Free Survival / Pathological Complete Response Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate Progression-Free Survival Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate Overall Survival / Disease-Free Survival / Pathological Complete Response Overall Survival / Disease-Free Survival / Pathological Complete Response Overall Survival / Disease-Free Survival / Pathological Complete Response Overall Survival / Disease-Free Survival / Pathological Complete Response Overall Survival / Disease-Free Survival / Pathological Complete Response Overall Survival / Disease-Free Survival / Pathological Complete Response Overall Survival / Disease-Free Survival / Pathological Complete Response Overall Survival / Disease-Free Survival / Pathological Complete Response Overall Survival / Disease-Free Survival / Pathological Complete Response Overall Survival / Disease-Free Survival / Pathological Complete Response Overall Survival / Disease-Free Survival / Pathological Complete Response Overall Survival / Disease-Free Survival / Pathological Complete Response Overall Survival / Disease-Free Survival / Pathological Complete Response Overall Survival / Disease-Free Survival / Pathological Complete Response	PRELIMINARY SCORE	FINAL SCORE
NON-CURATIVE ADJUSTMENTS Quality of life Progression-Free Survival Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate Serious and disabling adverse effects Overall Survival / Disease-Free Survival / Pathological Complete Response Overall Survival / Disease-Free Survival / Pathological Complete Response INFORMATION Tumour type: Thoracic Malignancies Threspeutic Incideation: Repotrectinib used for locality advanced or metastatic ROS1-positive non-small cell lung cancer. First FDA approval that includes patients with ROS1-positive non-small cell lung cancer. First FDA approval that includes patients with ROS1-positive Progression.	CURATIVE	CURATIVE
NON-CURATIVE ADJUSTMENTS Quality of life Progression-Free Survival Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate Serious and disabling adverse effects Overall Survival / Disease-Free Survival / Pathological Complete Response Overall Survival / Disease-Free Survival / Pathological Complete Response INFORMATION Tumour type: Thoracic Malignancies Threspeutic Incideation: Repotrectinib used for locality advanced or metastatic ROS1-positive non-small cell lung cancer. First FDA approval that includes patients with ROS1-positive non-small cell lung cancer. First FDA approval that includes patients with ROS1-positive Progression.		
ADJUSTMENTS Overall Survival Progression-Free Survival Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate Serious and disabling adverse effects Overall Response Rate / Duration of Response Overall Survival / Disease-Free Survival / Pathological Complete Response Other adjustments INFORMATION Turnour type: Thoracic Malignancies Therapeutic Indication: Repotrectinib used for locally advanced or metastatic ROS1-positive non-small cell lung cancer. First FDA approval that includes patients with ROS1-positive Non-are TKI naive. Experimental Arm: Repotrectinib used for locally advanced or metastatic ROS1-positive non-small cell lung cancer. First FDA approval that includes patients with ROS1-positive NoSCLC who are TKI naive.		Overall Survival / Disease-Free Survival / Pathological Complete Response
ADJUSTMENTS Overall Survival Progression-Free Survival Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate Serious and disabling adverse effects Overall Response Rate / Duration of Response Overall Survival / Disease-Free Survival / Pathological Complete Response Other adjustments INFORMATION Turnour type: Thoracic Malignancies Therapeutic Indication: Repotrectinib used for locally advanced or metastatic ROS1-positive non-small cell lung cancer. First FDA approval that includes patients with ROS1-positive Non-are TKI naive. Experimental Arm: Repotrectinib used for locally advanced or metastatic ROS1-positive non-small cell lung cancer. First FDA approval that includes patients with ROS1-positive NoSCLC who are TKI naive.	NON CURATIVE	
ADJUSTMENTS Quality of life Progression-Free Survival Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate Serious and disabling adverse effects Overall Response Rate / Duration of Response Overall Survival / Disease-Free Survival / Pathological Complete Response INFORMATION Tumour type: Thoracic Malignancies Therapeutic Indication: Repotrectinib used for locally advanced or metastatic ROS1-positive NoS1-positive NoS1-po		NON-CURATIVE
ADJUSTMENTS Quality of life Progression-Free Survival Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate Serious and disabling adverse effects Overall Response Rate / Duration of Response Overall Survival / Disease-Free Survival / Pathological Complete Response INFORMATION Tumour type: Thoracic Malignancies Therapeutic Indication: Repotrectinib used for locally advanced or metastatic ROS1-positive NoS1-positive NoS1-po		
Progression-Free Survival Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate Serious and disabling adverse effects Overall Response Rate / Duration of Response Overall Survival / Disease-Free Survival / Pathological Complete Response INFORMATION Tumour type: Thoracic Malignancies Therapeutic Indication: Repotrectinib used for locally advanced or metastatic ROS1-positive non-small cell lung cancer. First FDA approval that includes patients with ROS1-positive NSCLC who are TKI naïve. Experimental Arm: Repotrectinib	ADJUSTMENTS	Overall Survival
Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate Serious and disabling adverse effects Overall Response Rate / Duration of Response Overall Survival / Disease-Free Survival / Pathological Complete Response NFORMATION Tumour type: Thoracic Malignancies Therapeutic Indication: Repotrectinib used for locally advanced or metastatic ROS1-positive non-small cell lung cancer. First FDA approval that includes patients with ROS1-positive NSCLC who are TKI naïve. Experimental Arm: Repotrectinib	Quality of life	
Overall Response Rate / Duration of Response Overall Survival / Disease-Free Survival / Pathological Complete Response INFORMATION Tumour type: Thoracic Malignancies Therapeutic Indication: Repotrectinib used for locally advanced or metastatic ROS1-positive non-small cell lung cancer. First FDA approval that includes patients with ROS1-positive NSCLC who are TKI naïve. Experimental Arm: Repotrectinib		Progression-Free Survival
Overall Response Rate / Duration of Response Overall Survival / Disease-Free Survival / Pathological Complete Response INFORMATION Tumour type: Thoracic Malignancies Therapeutic Indication: Repotrectinib used for locally advanced or metastatic ROS1-positive non-small cell lung cancer. First FDA approval that includes patients with ROS1-positive NSCLC who are TKI naïve. Experimental Arm: Repotrectinib		
Overall Response Rate / Duration of Response Overall Survival / Disease-Free Survival / Pathological Complete Response INFORMATION Tumour type: Thoracic Malignancies Therapeutic Indication: Repotrectinib used for locally advanced or metastatic ROS1-positive non-small cell lung cancer. First FDA approval that includes patients with ROS1-positive NSCLC who are TKI naïve. Experimental Arm: Repotrectinib		Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate
Overall Response Rate / Duration of Response Overall Survival / Disease-Free Survival / Pathological Complete Response INFORMATION Tumour type: Thoracic Malignancies Therapeutic Indication: Repotrectinib used for locally advanced or metastatic ROS1-positive non-small cell lung cancer. First FDA approval that includes patients with ROS1-positive NSCLC who are TKI naïve. Experimental Arm: Repotrectinib	Serious and disabling adverse effects	
Overall Survival / Disease-Free Survival / Pathological Complete Response INFORMATION Tumour type: Thoracic Malignancies Therapeutic Indication: Repotrectinib used for locally advanced or metastatic ROS1-positive non-small cell lung cancer. First FDA approval that includes patients with ROS1-positive NSCLC who are TKI naïve. Experimental Arm: Repotrectinib		
Other adjustments INFORMATION Tumour type: Thoracic Malignancies Therapeutic Indication: Repotrectinib used for locally advanced or metastatic ROS1- positive non-small cell lung cancer. First FDA approval that includes patients with ROS1-positive NSCLC who are TKI naïve. Experimental Arm: Repotrectinib		Overall Response Rate / Duration of Response
Tumour type: Thoracic Malignancies Therapeutic Indication: Repotrectinib used for locally advanced or metastatic ROS1- positive non-small cell lung cancer. First FDA approval that includes patients with ROS1-positive NSCLC who are TKI naïve. Experimental Arm: Repotrectinib		Overall Survival / Disease-Free Survival / Pathological Complete Response
Therapeutic Indication: Repotrectinib used for locally advanced or metastatic ROS1-positive non-small cell lung cancer. First FDA approval that includes patients with ROS1-positive NSCLC who are TKI naïve. Experimental Arm: Repotrectinib	Other adjustments	INFORMATION
		Therapeutic Indication: Repotrectinib used for locally advanced or metastatic ROS1- positive non-small cell lung cancer. First FDA approval that includes patients with ROS1-positive NSCLC who are TKI naïve. Experimental Arm: Repotrectinib

